company-header-background

Transfection

Reagents

Ground-breaking Transfection Technology

Gene Transfection Kits for Primary Cells
• Up to 95% cell transfection efficiency
• No observed toxicity
• Same reagents in vitro and in vivo
• Easy to use with NanoAssemblr™ technology
• Non-viral transfection

Cell Types:
• Primary Neurons, Astrocytes, and mixed cultures
• iPS derived cells
• Hepatocytes

Nucleic Acids:
• Short interfering RNA (siRNA)
• Messenger RNA (mRNA)
• Plasmid DNA (pDNA)

Transfection Kits
Adapted from RNAi therapeutic technology currently in clinical trials, Precision NanoSystems’ non-viral gene transfection kits perform exceptionally well in cell types that are challenging to transfect with other methods (eg. transfection of primary cells). This technology encapsulates nucleic acids in lipid nanoparticles (LNPs) that mimic low-density lipoproteins (LDLs). LNPs take advantage of an endogenous pathway ubiquitous among mammalian cells to achieve high transfection efficiency (typically >90%) with no observable toxicity. Kits for use with different cell types and nucleic acid payloads including siRNA, messenger RNA (mRNA), and plasmid DNA (pDNA) are available. The kits are designed for use with NanoAssemblr™ systems established in the drug formulation and nanoparticle manufacturing field for ensuring high-quality reproducible results are achieved rapidly with minimal training.
Gene Transfection Kit: Primary Cell


Above Left: Primary rat neurons expressing GFP 48h after cell transfection with Neuro9-mRNA. Above Right: Primary rat neurons expressing GFP 48h following transfection with Neuro9-pDNA. Bottom: Rendition of the endogenous uptake pathway used by Precision NanoSystems’ transfection reagents to deliver nucleic acids in a non-toxic way.


Simple workflow for Spark Transfection Kit
Spark Transfection Kit Workflow

Simple workflow for NanoAssemblr® Benchtop Transfection Kit
Benchtop Transfection Kit Workflow

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to Liposomes

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Romano, D.T. O'Hagan, U. D'Oro, ...

Read More 阅读更多

Publication - Abstract

December 31, 2019

Vaccines

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerated in Healthy Adults ...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith, Ö. Almarsson, H.S. Pujar, M....

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, et al.

Read More 阅读更多

Publication - Summary

May 17, 2019

Science Immunology

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

N. Kose, J.M. Fox, G. Sapparapu, et al.

Read More 阅读更多

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More 阅读更多
Resource Center 资源中心
MENU
菜单
X
X